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Background: Patients with resistant hypertension are subjected to a higher risk of getting stroke, myocardial
infarction, congestive heart failure and renal failure. However, the exact prevalence of resistant hypertension in
treated hypertensive patients in Malaysia is not known. This paper examines the prevalence and determinants of
resistant hypertension in a sample of hypertensive patients.
Methods: We examined the control of blood pressure in a randomly selected sample of patients with hypertension
in a primary care clinic. Demographic data, blood pressure and anti-hypertensive drug use were captured from
patient records at the end of 2007. Resistant hypertension is defined as failure to achieve target blood pressure
of < 140/90 mmHg while on full doses of an appropriate three-drug regimen that includes a diuretic. Multivariate
logistic regression was used for the analysis.
Results: A total of 1217 patients with hypertension were entered into the analysis. Mean age of the patients was
66.8 ± 9.7 years and 64.4% were female. More than half of the subjects (56.9%) had diabetes mellitus. Median BP
was 130/80 mmHg. Overall prevalence of resistant hypertension was 8.8% (N = 107/1217). In multivariate logistic
regression analysis, presence of chronic kidney disease is more likely to be associated with resistant hypertension
(odds ratio [OR] 2.89, 95% confidence interval [CI] 1.56-5.35). On the other hand, increase per year of age is
associated with lower odds of resistant hypertension in this population (OR 0.96, 95% CI 0.93-0.99).
Conclusions: Resistant hypertension is present in nearly one in ten hypertensive patients on treatment.
Hypertensive patients who have underlying chronic kidney disease are associated with higher odds of having
resistant hypertension. Hence, in managing patients with hypertension, primary care physicians should be more
alert and identify patients with chronic kidney disease as such patients are more likely to develop resistant
hypertension. By doing that, these patients can be treated more aggressively earlier in order to achieve blood
pressure target and thus reduce cardiovascular events.
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Resistant hypertension is an important medical condition
as uncontrolled blood pressure (BP) is associated with a
fourfold risk of cardiovascular events compared with hyper-
tensive patients achieving BP targets [1,2]. The definition of
resistant hypertension varies. The Seventh Report of the
Joint National Committee on Prevention, Detection, Evalu-
ation, and Treatment of High BP defines resistant hyper-
tension as failure to achieve BP to target despite adherence
to appropriate treatment with full doses of at least 3 drug
regimens including a diuretic [3]. On the other hand, the
National Institute for Health and Care Excellence [4] and
the European Society of Hypertension guidelines do not in-
clude the use of a diuretic in their definition [5].
Studies also show that resistant hypertension is associ-
ated with increasing age, female gender, black race, pres-
ence of diabetes, obesity, chronic kidney disease and left
ventricular hypertrophy [6-14]. Early recognition of re-
sistant hypertension followed by aggressive treatment is
important to reduce both cardiovascular morbidity and
mortality. However the exact prevalence of resistant
hypertension is not precisely known due to its varied
definition [3,15] and the setting of where the study was
done. As such, based on several studies resistant hyper-
tension has been reported to range from 5% to 50%
[16-19]. Furthermore most studies on resistant hyperten-
sion were done in secondary care and very few have
been conducted in primary care.
Strokes are more common in Asia than in developed
countries while the reverse is true for coronary artery dis-
ease [20]. Elevated BP is one of the most important risk fac-
tors for stroke [21,22] and poorly controlled hypertension
increases this risk [3,23,24]. Hypertension is of particular
importance in South East Asia because while the preva-
lence of hypertension in Asian countries is nearly the same
as that of most developed countries [25] , unfortunately
many more patients in Asia with hypertension are not con-
trolled to target [26,27] compared to developed countries.
For example , in developed countries the control rates of
hypertension was around 52% [28] to 60% [29] but it is as
low as 26% in Malaysia [30]. Resistant hypertension is one
of the contributors of uncontrolled hypertension. Little is
known about the prevalence of resistant hypertension in
the South East Asian population. Hence we wanted to
examine prevalence of resistant hypertension in treated
hypertensive patients in a primary care setting in a South




We examined the control of blood pressure in a randomly
selected sample of patients in an urban primary care clinic.
Random numbers was generated by computer based on thepatient registration number with the clinic. This selected
sample consists of adult patients aged 30 years and older
with hypertension who were treated and on long term
follow-up in our primary care clinic. The study was con-
ducted in an outpatient clinic of the University Malaya
Medical Centre, a teaching hospital in Kuala Lumpur, the
capital city of Malaysia. This clinic is run by 14 family
medicine specialists, 30 vocational trainees in family medi-
cine and other medical officers. This tertiary hospital in-
cluding its primary care clinic serves a multi-ethnic
population of 450,000 in the surrounding area.
People in the community can choose their own source
of care. This teaching hospital functions on an open ac-
cess basis to the community. A full range of services are
offered at this clinic. Those who attend our clinic are
mainly those requiring long term care of chronic
conditions like hypertension, diabetes, dyslipidaemia in
addition to the usual short term primary care illnesses.
Care is provided free for public sector service em-
ployees and their dependents while all others are re-
quired to pay an equivalent of US$8.50 for both the
consultation and a month’s supply of medication. Our
study population consists of three main ethnic groups,
namely the Malays, Chinese and Indians [31].
Ethics approval for this study was obtained from the
Ethics Committee of the University of Malaya Medical
Centre.
Inclusion criteria
All patients with underlying hypertension were eligible
for this study. Hypertension was defined as those who
had a documented diagnosis of hypertension [i.e. BP ≥
140/90 mmHg] or those on anti-hypertensive agents.
Data collection
This sample was randomly selected using a computer gen-
erated number based on the patient’s unique registration
number with the clinic. All patient records were in paper
form. We extracted the patients’ information based on the
last entry in 2007 from their records manually according to
a predetermined proforma (clinical report form) which
included the patient’s socio demographic, blood pressure,
weight, height, biochemical profile and use of anti-
hypertensive agents. This was then entered into an elec-
tronic Excel spreadsheet and then converted to a SPSS
format for analysis using SPSS version 21.
The data was captured by a trained and experienced
abstractor and accuracy of data entry was checked by
the investigators themselves.
Patients’ blood pressure which was measured by the at-
tending doctors as part of daily routine care were also cap-
tured from the medical records. Patients recruited into our
study were those who had been diagnosed to have hyper-
tension or were on antihypertensive medications. Diagnosis
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standard recommendations i.e. based on at least 2 BP mea-
surements at least 2 weeks apart [3]. Height and weight had
been recorded using a stadiometer and digital weighing ma-
chine. We computed the body mass index (BMI) as weight
in kilograms per square meter height (kg/m2).
We used the Cockcroft-Gault formula to calculate the
estimated glomerular filtration rate (GFR) as a measure
of renal function. The presence of chronic kidney disease
(CKD) was defined as estimated GFR < 60 mL/min per
1.73 m2.
Anti-hypertensive drug use was also captured from
medical records and classified into the following classes:
renin-angiotensin-system (RAS) inhibitors encompass-
ing angiotensin-converting enzyme inhibitors (ACEI),
angiotensin receptor blockers (ARB); beta-blockers,
calcium-channel blocker (CCB), diuretics and alpha-
blockers N.
Resistant hypertension in this study is defined as office
BP ≥140 and/or 90 mmHg despite the use of at least
three antihypertensive drugs, one of which is a diuretic.
Diabetes mellitus (DM) was based on the doctors’ diag-
nosis or the use of hypoglycemic agents or both as
stated in the medical records. Smokers were defined as
current if they were still smoking; non smokers for those
who never smoked or currently not smoking, regardless
of when they had stopped smoking as indicated in the
patient records.Table 1 Clinical characteristics of the studied population
in UMMC (N = 1217)
Characteristic of the subjects
Mean Age ± SD ,years 66.8 ± 9.7





Systolic blood pressure (IQR), mmHg 130 (90–220)
Diastolic blood pressure (IQR), mmHg 80 (50–110)
Resistant hypertension, n, % 107 (8.8)
Presence of DM, n, % 693 (56.9)
Missing value, n % 20 (1.6%)
BMI (IQR), kg/m2 25.8 (12.9-55.5)Statistical analysis
All statistical analysis was done using the Statistical Package
for Social Sciences (SPSS version 21). Continuous data are
described as mean and standard deviation if the distribution
is normal. When the data was a skewed distribution, me-
dian, minimum and maximum value were used to describe
the data. Categorical data are reported as proportions
(percentage). Chi-square test or Fisher exact tests were used
for the categorical or dichotomous variables. Multivariate
logistic regression analysis was used to look for the predic-
tors of resistant hypertension. All variables with the p-value
of less than 0.25 in the univariate analyses as well as clinic-
ally significant variables were entered into the multivariate
logistic regression. The dependent variable was resistant
hypertension (yes or no). The independent variables were
age, gender, ethnicity, BMI, presence of diabetes, chronic
kidney disease, dyslipidaemia and smoking status. All ana-
lyses were done with 95% confidence intervals (CI), and the
level of significance was set at p < 0.05.Missing value, n, % 367 (30.2)
presence of CKD, n, % 425 (34.9)
Missing value, n, % 261 (21.4)
Smoker, n, % 86 (7.1)
IQR: interquartile range.Results
A total of 1222 hypertensive patients were eligible for this
study. Out of this, 1217 (99.6%) patients had complete drug
therapy data and were entered into the analysis.Table 1 shows the clinical characteristics of the studied
population. Overall, the mean age of the patients was
66.8 ± 9.7 years; about two-thirds were female (66.4%),
and 59% were aged more than 65 years. The median BP
was 130/80 mmHg. More than half of the populations
(56.9%) were diabetics with a mean HbA1c of 7.0 ± 1.7%.
The mean eGFR of the studied population was 62.7 ±
33.2 mL/ min per 1.73 m2 and a third (34.9%) of the
patients had underlying CKD.
The mean number of anti-hypertensive agents used
was 2.0 ± 1.0. The control rate of those on 2 drugs was
52.3% while it was 48.0% for those on 3 drugs. Three
fifths (60.9%) of the diabetics and two fifths (41.3%) of
the patients with CKD were on 3 antihypertensive
agents. Calcium-channel blockers were the most com-
monly prescribed drug (53.2%) followed by angiotensin
converting enzyme inhibitors or angiotensin receptor
blockers (51.0%), beta-blockers (44.5%), diuretics (32.5%)
and alpha-blockers (3.5%). For those patients who were
on at least three drugs, 70.2% (n = 181) were on di-
uretics and 29.8% (n = 77) were not on diuretics. Among
those patients who were on at least 3-antihypertensive
agents including diuretics, 40.9% (n = 74) achieved blood
pressure target while 59.1% (n = 107) had resistant
hypertension. On the other hand, of those on at least 3
antihypertensive drugs which did not include a diuretic
96.1%, (n = 74) were controlled and 3.9% (n = 3) were
not controlled.
Overall prevalence of resistant hypertension was 8.8%
(N = 107) with 95% confidence interval (CI) 7.21-10.39.
Table 2 Association between clinical variables among patients with and without resistant hypertension





Age (years) 66.9 ± 9.5 65.5 ± 9.5 0.15
Female, n, % 713 (64.2) 71 (66.4) 0.66
Ethnicity, n , %
Malay 281 (25.4) 31 (29.0) 0.99
Chinese 495 (44.7) 45 (42.1)
Indians 319 (28.8) 29 (27.1)
BMI, kg/m2 26.3 ± 4.8 27.4 ± 5.4 0.08
Diabetes mellitus, n, % 672 (61.3) 67 (62.6) 0.79
Dyslipidaemia, n, % 734 (66.1) 76 (71.0) 0.34
Chronic kidney disease, n, % 377 (43.5) 48 (53.3) 0.08
Smoker, n, % 77 (6.9) 9 (8.4) 0.93
HPT: hypertension, n: number, BMI: body mass index.
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without resistant hypertension.
Table 3 shows the results of multivariate logistic regres-
sions. After adjusting for all the variables in the model, age
and presence of CKD were the main predictors. Presence
of CKD among patients with hypertension were more likely
to be associated with resistant hypertension compared to
those without CKD (odds ratio [OR] 2.89, 95% CI 1.56-
5.35). Increasing age is less likely to be associated with re-
sistant hypertension (OR 0.96, 95% CI 0.93-0.99).
Discussion
The prevalence of resistant hypertension in this primary
care setting is 8.8%. This is lower than that reported inTable 3 Predictors of resistant hypertension at UMMC (N = 12
Variables Adjusted OR*
Chronic kidney disease 2.89
Body mass index (per 1 kg/m2 increase) 1.05











*Adjusted odds ratio CI: Confidence Interval. **p-value is <0.05.secondary care [8,32,33] but is similar to another primary
care study [18].
Our findings also show that hypertensive patients with
CKD had 2.9 odds of having resistant hypertension com-
pared to those without CKD. This is consistent with find-
ings in other studies [12,14]. One possible reason is that in
patients with CKD, there is increased sensitivity to salt
resulting in sodium and fluid retention, thus making BP
more difficult to control [34]. Another possible explanation
is that in CKD, the RAS system is up regulated resulting in
difficult to control BP [35].
Our study sample is made up of older patients as seen
from the mean age of 66.9 years. That resistant hyperten-
sion is negatively associated with age could be due to the17)
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ant hypertension had already succumbed to the complica-
tions of uncontrolled or resistant hypertension.
Previous studies have shown obesity to be associated
with resistant hypertension [3], although we only found
weak evidence (p = 0.08) for such an association. A pos-
sible reason could be because of our small sample size of
patients with resistant hypertension as the difference in
body mass index between patient with and without
hypertension resistant is not great (27.4 kg/m2 versus
26.3 kg/m2).
Furthermore studies have shown diabetes to be associ-
ated with resistant hypertension [1,8,12] but we could
not find any association in our study. This could be due
to only a small difference in HbA1c between these two
groups, where the mean HbA1c was 7.9 ± 2.0% among
patients with resistant hypertension versus HbA1c of
7.5 ± 1.7% in patients without resistant hypertension,
p = 0.139).
Many studies have shown that most patients with
hypertension need 2 or more drugs to achieve target BP
[36-38]. Not surprisingly because the mean number of
antihypertensive drugs used in our study was 2. We also
found poor control rates amongst those on only 2 drugs,
even those on 3 drugs had lower than 50% control rate.
When control is not to target particularly when patients
are already on 3 drugs, the recommendation is that one
of the drugs should be a diuretic. However we found
that overall the use of diuretics was low. The definition
of resistant includes use of a diuretic. Therefore, those
patients on triple antihypertensive therapy but not
including a diuretic, are not considered to have resistant
hypertension in this study. This may therefore result in
an underestimation of the true prevalence of resistant
hypertension in our population.
In our study, it is possible that interaction between
some of the factors of interest may explain the stron-
ger associations evident in the multivariate compared
with univariate regressions, particularly for CKD.
However, this was not evident when interaction terms
were included between CKD and BMI (p = 0.79) but
significant interaction found between CKD and age
(p < 0.001).
Strength and limitations
Our present study has several strengths and some
limitations. The strength of our study is that it is
done in the primary care setting where the prevalence
of resistant hypertension is different from that in
secondary care. Secondly, our sample size is large
enough to give us a better picture of the prevalence
of resistant hypertension in primary care.
A limitation of our study is that adherence to medication
was not available from the patient records. If adherence istaken into account, the “true” resistant hypertension may
be lower as many studies have shown that “resistant hyper-
tension” is frequently due to non-adherence. However doc-
tors in routine daily clinical practice are not accurate in
assessing adherence and even if adherence is assessed, this
information is seldom recorded. Pill counting or use of
electronic devices is indicated to confirm adherence, but
this may not be practical in a real clinical setting [39-41].
Conclusions
The prevalence of resistant hypertension in this pri-
mary care population of patients with hypertension is
relatively low. Nevertheless every effort is still needed
to recognize it early. The presence of CKD is associ-
ated with higher odds of having resistant hyperten-
sion. On the other hand, increase in one year of age
is associated with lower odds of having resistant
hypertension in this population. These results indicate
that clinicians should recognize resistant hypertension
earlier, especially in those who have CKD so that
early referral or intensifying therapy can be put in
place.
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